Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Sanbo Brain Hospital
About this trial
This study is intend to improve the objective response rate in treatment of camrelizumab in recurrent primary central nervous system lymphoma patients.
Eligibility criteria
Qualifiers
The initial diagnosis was primary diffuse large B-cell lymphoma of the central nervous system confirmed by histopathology;
Prior to first-line treatment based on methotrexate (with or without radiotherapy), tumor recurrence was confirmed by MRI;
Measurable focus in MRI (>10x10mm);
Aged > 18 years;
Disqualifiers
Concurrent administration of any other antitumor therapy；
Allergic to the ingredients of research drugs；
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent；
Any active autoimmune diseases or a history of autoimmune diseases (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, decreased thyroid function；
Trial design
Treatments tested in this trial
- Camrelizumab
Treatment groups
21 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov